Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus irinotecan-based therapy in AREG/EREG-high right-sided RAS/BRAF wild-type advanced colorectal cancer
ACTRN12623000874617Phase 2Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Progression-free survival. Started Oct 2024; status: recruiting.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12623000874617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000874617.